Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00250991 · ClinicalTrials.gov registry record · Phase 1
Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke (CLEAR Stroke) Trial
A Phase 1 study, sponsored by University of Cincinnati.
- Completed
- Registry status
- Phase 1
- Development phase
- 94
- Enrollment target
NCT00250991 is a Phase 1 study that has completed, run by University of Cincinnati. The registered enrollment target is 94 participants.
The verdict
NCT00250991, a Phase 1 study, has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 94 participants
- Enrollment target
Study Summary
The purpose of this study is determine the effects of using of a combination of two drugs--integrilin (eptifibatide) and activase (recombinant tissue plasminogen activator, rt-PA, or recombinant t-PA)--to dissolve blood clots in patients who have a stroke.
Interventions
- DRUG activase
- DRUG integrilin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2003-07 |
| Est. Completion | 2007-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00250991
The ClinicalTrials.gov registry entry for NCT00250991 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which activase is the first listed.
NCT00250991 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00250991 about?
NCT00250991 is a clinical study titled "Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke (CLEAR Stroke) Trial". The purpose of this study is determine the effects of using of a combination of two drugs--integrilin (eptifibatide) and activase (recombinant tissue plasminogen activator, rt-PA, or recombinant t-PA)--to dissolve blood clots in patients who have a stroke.
What is the current status of trial NCT00250991?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 94 participants. The study started on 2003-07. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00250991?
The interventions under investigation include: activase (DRUG), integrilin (DRUG).
Who is sponsoring clinical trial NCT00250991?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.